1. PO.1.12 Transcriptome profiling and autoimmunity-related serological markers identify TP53 and C3aR as drug targets in neuropsychiatric systemic lupus erythematosus. (27th September 2022) Authors: Lindblom, J; Toro-Domínguez, D; Carnero-Montoro, E; Borghi, MO; Castillo, J; Iacobaeus, E; Enman, Y; Repsilber, D; Mohan, C; Alarcón-Riquelme, M; Barturen, G; Parodis, I Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO.1.21 Attainment of EQ-5D-3L full health state after therapy is associated with decelerated organ damage accrual in systemic lupus erythematosus. (27th September 2022) Authors: Lindblom, J; Zetterberg, S; Borg, A; Emamikia, S; Von Perner, G; Enman, Y; Heintz, E; Regardt, M; Grannas, D; Gomez, A; Parodis, I Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO.2.27 Early changes in the circulating B cell compartment associated with response to treatment and occurrence of flares in patients receiving therapy for active systemic lupus erythematosus. (27th September 2022) Authors: Gatto, M; Gomez Gonzales, A; Lindblom, J; Doria, A; Parodis, I Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PO.4.92 Taxonomy, treatment, targets and remission in systemic lupus erythematosus: the 3TR-SLE study protocol. (27th September 2022) Authors: Parodis, I; Voskuyl, AE; Alarcón-Riquelme, ME; Beretta, L Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification. (27th September 2022) Authors: Parodis, I; Liefaard, L; Green, Y; Gilbride, JA; Henning, C; Levy, RA; Dimelow, R Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE. (27th September 2022) Authors: Jägerback, S; Gomez, A; Parodis, I Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PO.5.99 Drug repurposing for treating lupus nephritis based on transcriptome profiling and autoimmunity-related serological markers. (27th September 2022) Authors: Parodis, I; Lindblom, J; Toro-Domínguez, D; Carnero-Montoro, E; Borghi, MO; Castillo, J; Enman, Y; Repsilber, D; Mohan, C; Alarcón-Riquelme, M; Barturen, G Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PO.6.119 Low-dose belimumab and antimalarial agents prevent renal flares in systemic lupus erythematosus: results from four randomised clinical trials. (27th September 2022) Authors: Gomez, A; Jägerback, S; Sjöwall, C; Parodis, I Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PO.6.120 Non-pharmacological management of systemic lupus erythematosus and systemic sclerosis: a systematic literature review to inform eular recommendations. (27th September 2022) Authors: Parodis, I; Gomez, A; Tsoi, A; Chow, JW; Pezzella, D; Girard, C; Stamm, T; Boström, C Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry. (27th September 2022) Authors: Walhelm, T; Wirestam, L; Parodis, I; Sjöwall, C Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗